| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Research Articles: Targets
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
1 The Wistar Institute, and 2 Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Requests for reprints: Keiran S.M. Smalley, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104. Phone: 215-898-3951. E-mail: ksmalley{at}wistar.org
Although >66% of melanomas harbor activating mutations in BRAF and exhibit constitutive activity in the mitogen-activated protein kinase/extracellular signal–regulated kinase kinase (MEK)/extracellular signal–regulated kinase signaling pathway, it is unclear how effective MEK inhibition will be as a sole therapeutic strategy for melanoma. We investigated the anticancer activity of MEK inhibition in a panel of cell lines derived from radial growth phase (WM35) and vertical growth phase (WM793) of primary melanomas and metastatic melanomas (1205Lu, 451Lu, WM164, and C8161) in a three-dimensional spheroid model and found that the metastatic lines were completely resistant to MEK inhibition (U0126 and PD98059) but the earlier stage cell lines were not. Similarly, these same metastatic melanoma lines were also resistant to inhibitors of the phosphatidylinositol 3-kinase/Akt pathway (LY294002 and wortmannin). Under adherent culture conditions, the MEK inhibitors blocked growth through the induction of cell cycle arrest and up-regulation of p27, but this was readily reversible following inhibitor washout. However, when the phosphatidylinositol 3-kinase and MEK inhibitors were combined, the growth and invasion of the metastatic melanoma three-dimensional spheroids were blocked. Taken together, these results suggest that the most aggressive melanomas are resistant to strategies targeting one signaling pathway and that multiple signaling pathways may need to be targeted for maximal therapeutic efficacy. It is further suggested that BRAF mutational status is not predictive of response to MEK inhibition under three-dimensional culture conditions. [Mol Cancer Ther 2006;5(5):1136–44]
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: K.S.M. Smalley and N.K. Haass contributed equally to this work.
3 Supplementary materials for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
Received 2/14/06; accepted 3/13/06.
This article has been cited by other articles:
|
|
 |
|
  M. A. Tran, R. Gowda, A. Sharma, E.-J. Park, J. Adair, M. Kester, N. B. Smith, and G. P. Robertson Targeting V600EB-Raf and Akt3 Using Nanoliposomal-Small Interfering RNA Inhibits Cutaneous Melanocytic Lesion Development Cancer Res., September 15, 2008; 68(18): 7638 - 7649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lioni, K. Noma, A. Snyder, A. Klein-Szanto, J. A. Diehl, A. K. Rustgi, M. Herlyn, and K. S.M. Smalley Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway Mol. Cancer Ther., September 1, 2008; 7(9): 2866 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S.M. Smalley, M. Lioni, M. D. Palma, M. Xiao, B. Desai, S. Egyhazi, J. Hansson, H. Wu, A. J. King, P. Van Belle, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol. Cancer Ther., September 1, 2008; 7(9): 2876 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S.M. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, A. J. King, K. T. Flaherty, M. Bosenberg, M. Herlyn, et al. Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression Cancer Res., July 15, 2008; 68(14): 5743 - 5752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Tran, C. D. Smith, M. Kester, and G. P. Robertson Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development Clin. Cancer Res., June 1, 2008; 14(11): 3571 - 3581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Madhunapantula, D. Desai, A. Sharma, S. J. Huh, S. Amin, and G. P. Robertson PBISe, a novel selenium-containing drug for the treatment of malignant melanoma Mol. Cancer Ther., May 1, 2008; 7(5): 1297 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tsai, J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N. K. Haass, et al. From the Cover: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity PNAS, February 26, 2008; 105(8): 3041 - 3046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, and K. S.M. Smalley The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel Clin. Cancer Res., January 1, 2008; 14(1): 230 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Hennessy, Y. Lu, E. Poradosu, Q. Yu, S. Yu, H. Hall, M. S. Carey, M. Ravoori, A. M. Gonzalez-Angulo, R. Birch, et al. Pharmacodynamic Markers of Perifosine Efficacy Clin. Cancer Res., December 15, 2007; 13(24): 7421 - 7431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression Cancer Res., December 1, 2007; 67(23): 11300 - 11308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. F. Wang, C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang, and P. Hersey Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1 Clin. Cancer Res., August 15, 2007; 13(16): 4934 - 4942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fukunaga-Kalabis, L. Li, and M. Herlyn Three-Dimensional Culture of Human Skin Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 203 - 206. [Full Text] [PDF]
|
|
|
|
|
|
W. Jiang, P. J. Mikochik, J. H. Ra, H. Lei, K. T. Flaherty, J. D. Winkler, and F. R. Spitz HIV Protease Inhibitor Nelfinavir Inhibits Growth of Human Melanoma Cells by Induction of Cell Cycle Arrest Cancer Res., February 1, 2007; 67(3): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lioni, P. Brafford, C. Andl, A. Rustgi, W. El-Deiry, M. Herlyn, and K. S.M. Smalley Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells Am. J. Pathol., February 1, 2007; 170(2): 709 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S.M. Smalley, R. Contractor, N. K. Haass, A. N. Kulp, G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, K. T. Flaherty, M. S. Soengas, E. Meggers, et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells Cancer Res., January 1, 2007; 67(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. King, D. R. Patrick, R. S. Batorsky, M. L. Ho, H. T. Do, S. Y. Zhang, R. Kumar, D. W. Rusnak, A. K. Takle, D. M. Wilson, et al. Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885 Cancer Res., December 1, 2006; 66(23): 11100 - 11105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Verhaegen, J. A. Bauer, C. Martin de la Vega, G. Wang, K. G. Wolter, J. C. Brenner, Z. Nikolovska-Coleska, A. Bengtson, R. Nair, J. T. Elder, et al. A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase-Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species Cancer Res., December 1, 2006; 66(23): 11348 - 11359. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
